Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan– March 24, 2014 – Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained the marketing approval of oral androgen receptor signaling inhibitor, XTANDI®...
Leiden, The Netherlands, March 20, 2014 - The Pediatric Praziquantel Consortium, launched in 2012 as an international non-profit public-private partnership, has announced that it has been awarded...
TOKYO, JAPAN and SAN FRANCISCO, CA – March 18, 2014 – Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application...
Tokyo, Japan – March 19, 2014 – Astellas Pharma Inc. (“Astellas”; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited (“Daiichi Sankyo,” President...
Follow us
